Business
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
SAN ANTONIO, March 19, 2025--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.
About this update from Bioaffinity Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":939,"height":303,"url":"https://media.zenfs.com/en/business-wire.com/6813bd234067765715ffdcd2eeaae2a4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TU0Spm9YkdfPpFbI45MIsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6813bd234067765715ffdcd2eeaae2a4","width":939,"height":303},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JCPqRZA86_AcmfeJO82EZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE4Nzg7aD02MDY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6813bd234067765715ffdcd2eeaae2a4","width":939,"height":303}},"lazy":false},{"type":"text","content":"Case Demonstrates CyPath® Lung’s Potential in Guiding Oncological Care","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"SAN ANTONIO, March 19, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient.","length":307,"tagName":"p"},{"type":"text","content":""This case exemplifies how CyPath® Lung can play a crucial role not only in lung cancer diagnostics but also in broader oncological decision-making, helping to guide clinical strategies and improve patient outcomes while reducing risky invasive procedures," bioAffinity Technologies’ President and Chief Executive Officer Maria Zannes said.","length":350,"tagName":"p"},{"type":"text","content":"The patient, a former smoker with COPD who was treated successfully for breast cancer in 2019, was under surveillance for lung cancer due to her history. A routine low-dose CT scan detected indeterminate nodules, including an eight-millimeter non-calcified nodule in her left upper lung lobe. "Given her risk factors and the fact that I’ve been following her with CT scans, this finding was very worrisome," Gordon H. Downie, MD, PhD, Director of the Pulmonary Nodule Clinic at Titus Regional Medical Center in Mount Pleasant, Texas, said.","length":549,"tagName":"p"},{"type":"text","content":"Traditional diagnostic approaches presented challenges. A PET scan was unlikely to provide clarity due to the lesion...